Overview

S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma

Status:
Active, not recruiting

Trial end date:
2023-06-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies can locate tumor cells and either kill them or deliver radioactive tumor-killing substances to them without harming normal cells. It is not yet known which monoclonal antibody plus combination chemotherapy regimen is more effective in treating non-Hodgkin's lymphoma. PURPOSE: This randomized phase III trial is comparing 2 different monoclonal antibodies given together with combination chemotherapy to see how well they work in treating patients with newly-diagnosed non-Hodgkin's lymphoma.

Phase:

Phase 3

Details

Lead Sponsor:

Southwest Oncology Group

Collaborators:

Cancer and Leukemia Group B
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Treatments:

Antibodies
Antibodies, Monoclonal
Cyclophosphamide
Doxorubicin
Immunoglobulins
Iodine
Iodine-131 anti-B1 antibody
Liposomal doxorubicin
Prednisone
Rituximab
Vincristine